Management of complications following leprosy: An evolving scenario

References

• Kumar B., Dogra S., Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis 2004; 72: 125–33
   PubMedGoogle Scholar
• Ishii N. Recent advances in the treatment of leprosy. Dermatol Online J 2003; 9((2))5
   PubMedGoogle Scholar
• Daumerie D. Current World Health Organization sponsored studies in the chemotherapy of leprosy. Lep Rev 2000; 71: 88–90
   PubMedGoogle Scholar
• Naafs B. Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. Int J Lepr Other Mycobact Dis 1996; 64: S21–8
   Google Scholar
• Britton W. J. The management of leprosy reversal reactions. Lepr Rev 1998; 69: 225–34
   PubMedGoogle Scholar
• Naafs B. Treatment duration of reversal reaction: A reappraisal. Back to the past. Lepr Rev 2003; 74: 328–36
   PubMed Web of Science ®Google Scholar
• Smith W. C. S. Review of current research in the prevention of nerve damage in leprosy. Lepr Rev 2000; 71: S138–45
   Google Scholar
• Katoch K. Therapeutic prospects for pauci‐bacillary leprosy. Indian J Lepr 2000; 72: 351–61
   PubMedGoogle Scholar
• Van Brakel W. H., Khawas I. B. Silent neuropathy in leprosy: An epidemiological description. Lepr Rev 1994; 65: 350–60
   PubMedGoogle Scholar
• Anonymous. Draft resolution: Sixth meeting of the WHO technical advisory group on elimination of leprosy (TAG). World Health Organization, Geneva February 2004
   Google Scholar
• Lockwood D. N. The management of erythema nodosum leprosum: Current and future options. Lepr Rev 1996; 67: 253–9
   PubMedGoogle Scholar
• Anonymous. Leprosy – global situation. Wkly Epidemiol Rec 2000; 75: 226–31
   PubMedGoogle Scholar
• Mahajan V. K., Sharma N. L., Sharma R. C., Sharma A. Pulse dexamethasone, oral steroids and azathioprine in the management of erythema nodosum leprosum. Lepr Rev 2003; 74: 171–4
   PubMedGoogle Scholar
• Sehgal V. N., Sardana K. Lepra vaccine: Misinterpreted myth. Int J Dermatol 2006; 45: 164–7
   PubMedGoogle Scholar
• Dasananjali K., Schreuder P. A., Pirayavaraporn C. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984–1996. Int J Lepr Other Mycobact Dis 1997; 65: 28–36
   PubMedGoogle Scholar
• Gebre S., Saunderson P., Byass P. Relapses after fixed duration multiple drug therapy: The AMFES cohort. Lepr Rev 2000; 71: 325–31
   PubMedGoogle Scholar
• Boerrigter G., Ponnighaus J. M., Fine P. E., Wilson R. J. Four‐year follow‐up results of a WHO‐recommended multiple‐drug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr Other Mycobact Dis 1991; 59: 255–61
   PubMedGoogle Scholar
• Schreuder P. A. The occurrence of reactions and impairments in leprosy: Experience in the leprosy control program of three provinces in northeastern Thailand, 1987–1995 [correction of 1978–1995]. I. Overview of the study. Int J Lepr Other Mycobact Dis 1998; 66: 149–58
   PubMedGoogle Scholar
• Shetty V. P., Wakade A. V., Ghate S., Pai V. V., Ganapati R., Antia N. H. Viability and drug susceptibility testing of M leprae using mouse footpad in 37 relapse cases of leprosy. Int J Lepr Other Mycobact Dis 2003; 71: 210–17
   PubMedGoogle Scholar
• Anonymous. WHO Expert Committee on leprosy. World Health Organ Tech Rep Ser 1998; 874: 1–43
   PubMedGoogle Scholar
• Shaw I. N., Natrajan M. M., Rao G. S., Jesudasan K., Christian M., Kavitha M. Long term follow‐up of multibacillary patients with high BI treated with WHO/MDT regimen for a fixed duration of two years. Int J Lepr Other Mycobact Dis 2000; 68: 405–9
   PubMedGoogle Scholar
• Jamet P., Ji B. Relapse after long‐term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis 1996; 63: 195–201
   Google Scholar
• Ramu G. Clinical features and diagnosis of relapses in leprosy. Indian J Lepr 1995; 67: 45–59
   PubMedGoogle Scholar
• Ji B. Drug resistance in leprosy – a review. Lepr Rev 1985; 56: 265–78
   PubMedGoogle Scholar
• Jacobson R. R. Treatment of leprosy. Leprosy, R Hastings. Churchill Livingstone, Edinburgh 1994; 68
   Google Scholar
• Report of the International Leprosy Association Technical Forum. 25–28 February 2002. Paris, France., Lepr Rev. 73. S27–34
   Google Scholar
• Maeda S., Matsuoka M., Nakata N., Kai M., Maeda Y., Hashimoto K., et al. Multidrug resistant Mycobacterium leprae from patients with leprosy. Antimicrob Agents Chemother 2001; 45: 3635–9
   PubMed Web of Science ®Google Scholar
• Cambau E., Bonnafous P., Perani E., Sougakoff W., Ji B., Jarlier V. Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin Infect Dis 2002; 34: 39–45
   PubMed Web of Science ®Google Scholar
• Visschedijk J., van de Broek J., Eggens H., Lever P., van Beers S., Klatser P. Mycobacterium leprae – millennium resistant! Leprosy control on the threshold of a new era. Trop Med Int Health 2000; 5: 388–99
   PubMedGoogle Scholar
• Goulart I. M., Arbex G. L., Carneiro M. H., Rodrigues M. S., Gadia R. Adverse effects of multidrug therapy in leprosy patients: Five year survey at a health center of the federal university of Uberlandia. Rev Soc Bras Med Trop 2002; 35: 453–60
   PubMedGoogle Scholar
• Anonymous. WHO model prescribing information – drug used in leprosy., World Health Organization: Geneva; 1998. WHO/DMP/DSI/98.1.
   Google Scholar
• Anonymous. Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser 1982; 675: 1–33
   PubMedGoogle Scholar
• Mendiratta V. R., Sharma R. C., Sardana K., Koranne R. V. Smear positive leprosy with HIV infection, silent neuritis and extensive tinea corporis and tinea unguium in an Indian male. Indian J Lepr 2001; 73: 349–52
   PubMedGoogle Scholar
• Narang T., Dogra S., Kaur I. Borderline tuberculoid leprosy with type 1 reaction in an HIV patient – a phenomenon of immune reconstitution. Int J Lepr Other Mycobact Dis 2005; 73: 203–5
   PubMedGoogle Scholar
• Couppie P., Abel S., Voinchet H., Roussel M., Helenon R., Huerre M., et al. Immune reconstitution inflammatory syndrome associated with HIV and leprosy. Arch Dermatol 2004; 140: 997–1000
   PubMedGoogle Scholar
• Lockwood D. N., Sinha H. H. Pregnancy and leprosy: A comprehensive literature review. Int J Lepr Other Mycobact Dis 1999; 67: 6–12
   PubMedGoogle Scholar
• Bhattacharya S. N., Sehgal V. N. Reappraisal of the drifting scenario of leprosy multi‐drug therapy: New approach proposed for the new millennium. Int J Dermatol 2002; 41: 321–6
   PubMed Web of Science ®Google Scholar
• Anonymous. Report on the fifth meeting of the WHO technical advisory group on elimination of leprosy. World Health Organization, Geneva 2003
   Google Scholar
• Ji B. Accompanied MDT (A‐MDT) – more questions than answers. Lepr Rev 2002; 73: 301–307
   PubMedGoogle Scholar
• Ellard G. A., Pannikar V. K., Jesudasan K., Christian M. Clofazimine and dapsone compliance in leprosy. Lepr Rev 1988; 59: 205–13
   Google Scholar
• Becx‐Bleumink M. Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis 1992; 60: 436–44
   PubMedGoogle Scholar
• Anonymous. World Health Organization. Report on the third meeting of the WHO technical advisory group on elimination of leprosy. World Health Organization, Geneva, 2002. WHO/CDS/CPE/CEE/2002.29
   Google Scholar
• Anonymous. Report on the fourth meeting of the WHO technical advisory group on elimination of leprosy. World Health Organization, Geneva 2002
   Google Scholar
• Ji B., Saunderson P. Uniform MDT (U‐MDT) regimen for all leprosy patients – another example of wishful thinking. Lepr Rev 2003; 74: 2–6
   PubMedGoogle Scholar
• Meima A., Richardus J. H., Habbema J. D. Trends in leprosy case detection worldwide since 1985. Lepr Rev 2004; 75: 19–33
   PubMed Web of Science ®Google Scholar
• Anonymous. Report on the eighth meeting of the WHO technical advisory group on leprosy control. World Health Organization, Geneva, WHO‐SEA‐GLP‐2006.3
   Google Scholar
• Meima A., Smith W. C. S., van Oortmarssen G. J., Richardus J. H., Habbema J., Dik F. The future incidence of leprosy: A scenario analysis. Bull World Health Organ 2004; 82: 373–80
   PubMedGoogle Scholar